Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-ranging Study of AMG 133 in Overweight or Obesity With or Without Type 2 Diabetes Mellitus
2023-510470-13-00Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2024
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of maridebart cafraglutide in Overweight, obesity and type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by Amgen. Primary endpoint: Percent change from baseline to week 52 in body weight. Started Jun 2024; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
Overweightobesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-510470-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510470-13-00.